Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Molecular Assessment and Profiling of Liver Transplant Recipients

NCT: NCT04793360 · ACTIVE_NOT_RECRUITING

NCT IDNCT04793360
StatusACTIVE_NOT_RECRUITING
Start Date2021-05-26
Completion2028-03-31
SponsorCareDx (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of this protocol is to conduct longitudinal and prospective studies of liver transplant recipients, using a multimodality approach, akin to that used in kidney transplantation. The primary aim will compare the clinical outcomes of LiverCare post-transplant surveillance in liver transplant with standard of care consisting of liver function tests, DSA measurements, drug level monitoring, and 'for cause' biopsy. The protocol will assess the correlation between clinical events (e.g. rejection, recurrent disease, biliary obstruction), dd-cfDNA levels, gene expression profiling, ability to assess microchimerism, develop predictive analytics, infectious disease diagnoses and finally examine graft histology.

Frequently Asked Questions

What is Molecular Assessment and Profiling of Liver Transplant Recipients?

Molecular Assessment and Profiling of Liver Transplant Recipients is a clinical trial registered under NCT04793360. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04793360?

The current status of NCT04793360 (Molecular Assessment and Profiling of Liver Transplant Recipients) is: ACTIVE_NOT_RECRUITING.

When did Molecular Assessment and Profiling of Liver Transplant Recipients start?

Molecular Assessment and Profiling of Liver Transplant Recipients started on 2021-05-26.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.